Moreover, elevated STC2 is associated with poor outcomes in pancreatic, nasopharyngeal, ovarian, colon, and lung cancers, suggesting its role as a prognostic marker although, its role in breast cancer is controversial (63-65). This evidence concerns the gene STC2 and breast carcinoma.